ロード中...
Alemtuzumab for multiple sclerosis
BACKGROUND: Multiple sclerosis (MS) is an autoimmune, T‐cell‐dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating exacerbations, preventing new exacerbations and avoiding the progression of disability. Howe...
保存先:
| 出版年: | Cochrane Database Syst Rev |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Ltd
2016
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6486037/ https://ncbi.nlm.nih.gov/pubmed/27082500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011203.pub2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|